Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT NSCLC Vaccine Combination Immunotherapy
NCT03169738Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Feb 2018
- Primary completion
- Jan 2019
- Modality
- Adenoviral Vectors, DNA Vaccines, Peptide-based Cancer Vaccines
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, haNK, ETBX-011, ETBX-021, ETBX-051 in non-small cell lung cancer (NSCLC), sponsored by ImmunityBio, Inc.. Planned start Feb 2018; status: withdrawn.
02
Drugs
nogapendekin alfa inbakicepthaNKETBX-011ETBX-021ETBX-051
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03169738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03169738.